These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1254 related articles for article (PubMed ID: 8221424)

  • 1. Interactions between physicians and the pharmaceutical industry: what does the literature say?
    Lexchin J
    CMAJ; 1993 Nov; 149(10):1401-7. PubMed ID: 8221424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physicians and the pharmaceutical industry: is a gift ever just a gift?
    Wazana A
    JAMA; 2000 Jan; 283(3):373-80. PubMed ID: 10647801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interactions between physicians and the pharmaceutical industry generally and sales representatives specifically and their association with physicians' attitudes and prescribing habits: a systematic review.
    Fickweiler F; Fickweiler W; Urbach E
    BMJ Open; 2017 Sep; 7(9):e016408. PubMed ID: 28963287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Doctors and detailers: therapeutic education or pharmaceutical promotion?
    Lexchin J
    Int J Health Serv; 1989; 19(4):663-79. PubMed ID: 2583883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmaceutical industry support for continuing medical education programs: a review of current ethical guidelines.
    Rosner F
    Mt Sinai J Med; 1995 Nov; 62(6):427-30. PubMed ID: 8692156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Teaching appropriate interactions with pharmaceutical company representatives: the impact of an innovative workshop on student attitudes.
    Wofford JL; Ohl CA
    BMC Med Educ; 2005 Feb; 5(1):5. PubMed ID: 15698480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Continuing medical education and pharmaceutical industry involvement: An evaluation of policies adopted by Canadian professional medical associations.
    Shnier A; Lexchin J
    Int J Risk Saf Med; 2017; 29(1-2):1-16. PubMed ID: 28885217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Is it pertinent to investigate the relations between physicians and the drug industry].
    Moliner J; Mozota J; Abad JM; Casaña L; Júdez D; Rabanaque MJ
    Rev Calid Asist; 2009 Apr; 24(2):72-9. PubMed ID: 19426930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dangerous liaisons: doctors-in-training and the pharmaceutical industry.
    Pokorny AM; Gittins CB
    Intern Med J; 2015 Oct; 45(10):1085-8. PubMed ID: 26429220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medical students' exposure to and attitudes about drug company interactions: a national survey.
    Sierles FS; Brodkey AC; Cleary LM; McCurdy FA; Mintz M; Frank J; Lynn DJ; Chao J; Morgenstern BZ; Shore W; Woodard JL
    JAMA; 2005 Sep; 294(9):1034-42. PubMed ID: 16145023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effects of a mandatory guideline that prohibit hospital doctors from accepting any form of benefits in any form from the pharmaceutical industry].
    Gundermann C; Meier-Hellmann A; Bauer M; Hartmann M
    Dtsch Med Wochenschr; 2010 May; 135(3):67-70. PubMed ID: 20077378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmaceutical industry-sponsored meetings: good value or just a free meal?
    Carney SL; Nair KR; Sales MA; Walsh J
    Intern Med J; 2001 Nov; 31(8):488-91. PubMed ID: 11720063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between physicians' interaction with pharmaceutical companies and their clinical practices: A systematic review and meta-analysis.
    Brax H; Fadlallah R; Al-Khaled L; Kahale LA; Nas H; El-Jardali F; Akl EA
    PLoS One; 2017; 12(4):e0175493. PubMed ID: 28406971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Information from pharmaceutical companies and the quality, quantity, and cost of physicians' prescribing: a systematic review.
    Spurling GK; Mansfield PR; Montgomery BD; Lexchin J; Doust J; Othman N; Vitry AI
    PLoS Med; 2010 Oct; 7(10):e1000352. PubMed ID: 20976098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in drug prescribing patterns related to commercial company funding of continuing medical education.
    Bowman MA; Pearle DL
    J Contin Educ Health Prof; 1988; 8(1):13-20. PubMed ID: 10294441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of pharmaceutical firm enticements on physician prescribing patterns. There's no such thing as a free lunch.
    Orlowski JP; Wateska L
    Chest; 1992 Jul; 102(1):270-3. PubMed ID: 1623766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Conflict of interest in continuing medical education - Studies on certified CME courses].
    Lenzen LM; Weidringer JW; Ollenschläger G
    Z Evid Fortbild Qual Gesundhwes; 2016; 110-111():60-8. PubMed ID: 26875037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A survey of german physicians in private practice about contacts with pharmaceutical sales representatives.
    Lieb K; Brandtönies S
    Dtsch Arztebl Int; 2010 Jun; 107(22):392-8. PubMed ID: 20574555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do doctors rely on pharmaceutical industry funding to attend conferences and do they perceive that this creates a bias in their drug selection? Results from a questionnaire survey.
    Rutledge P; Crookes D; McKinstry B; Maxwell SR
    Pharmacoepidemiol Drug Saf; 2003 Dec; 12(8):663-7. PubMed ID: 14762982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparative evaluation of sponsored and unsponsored continuing medical education].
    Chon SH; Lösche P; Christ H; Lehmacher W; Griebenow R
    Med Klin (Munich); 2008 May; 103(5):341-5. PubMed ID: 18484220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 63.